Company intelligence / Profile preview
Caring Cross
- Ownership
- Private
- Development stage
- Phase 1
Overview
Caring Cross has developed advanced platforms enabling decentralized, point-of-care manufacturing of CAR-T cell and stem cell gene therapies. Their technologies have been transferred to partners globally, including India’s first approved commercial CAR-T product via ImmunoACT. They focus on making these treatments affordable through innovative business models and local manufacturing partnerships. Clinical results from their platforms have demonstrated therapeutic benefits in trials conducted by partner centers.
- Therapeutic areas
- OncologyRare DiseasesInfectious Diseases
- Modalities
- CAR-T cell therapiesStem cell gene therapiesLentiviral vector-based gene therapy
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Caring Cross.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Caring Cross.